Should I buy or sell Idorsia stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 4 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" IDRSF shares. View IDRSF analyst ratings or view top-rated stocks .

How have IDRSF shares performed in 2024?

Idorsia's stock was trading at $2.45 at the beginning of 2024. Since then, IDRSF shares have decreased by 17.1% and is now trading at $2.03. View the best growth stocks for 2024 here .

Are investors shorting Idorsia?

Idorsia saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,420,100 shares, a decline of 7.6% from the March 15th total of 9,112,700 shares. Based on an average trading volume of 6,500 shares, the short-interest ratio is presently 1,295.4 days. View Idorsia's Short Interest .

How do I buy shares of Idorsia?

Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IDRSF

Idorsia (IDRSF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free IDRSF Stock Alerts

$2.03

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.03
▼
$2.03
50-Day Range: $1.50
▼
$2.80
52-Week Range: $1.40
▼
$10.70

Volume: N/A
Average Volume: 3,788 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Idorsia alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Idorsia Stock (OTCMKTS:IDRSF)

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

IDRSF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IDRSF Stock News Headlines

April 17, 2024 | finance.yahoo.com

Idorsia publishes a Financial Status required for an upcoming bondholder meeting

April 17, 2024 | americanbankingnews.com

Idorsia Ltd (OTCMKTS:IDRSF) Short Interest Down 7.6% in March

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

April 11, 2024 | globenewswire.com

Idorsia takes steps to address short-term liquidity needs

March 22, 2024 | bizjournals.com

Idorsia gets FDA approval for high blood pressure drug Tryvio

March 22, 2024 | seekingalpha.com

Idorsia: Aprocitentan Approval Is A Vital News

March 22, 2024 | globenewswire.com

Idorsia thanks Guy Braunstein for his years of service as he retires

March 20, 2024 | msn.com

FDA approves Idorsia’s once-daily antihypertensive Tryvio

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 20, 2024 | msn.com

Idorsia gets FDA approval for hypertension drug Tryvio

March 20, 2024 | finance.yahoo.com

Idorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo Finance

March 20, 2024 | globenewswire.com

US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives

March 8, 2024 | finance.yahoo.com

What Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their Estimates

March 7, 2024 | realmoney.thestreet.com

Kepler Cheuvreux gets more bullish on Idorsia, upgrades shares

February 28, 2024 | markets.businessinsider.com

Viatris, Idorsia Announce Global Research And Development Collaboration

February 6, 2024 | markets.businessinsider.com

Here's what to expect from Idorsia's earnings

January 10, 2024 | finance.yahoo.com

Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation

December 6, 2023 | finance.yahoo.com

Idorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insiders

October 25, 2023 | msn.com

Idorsia Q3 Review: Not The Quarter We Expected

October 24, 2023 | msn.com

Idorsia GAAP EPS of CHF0.96, revenue of CHF80M

October 24, 2023 | finance.yahoo.com

Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value

October 24, 2023 | marketwatch.com

Idorsia Shares Fall on Funding Needs

October 23, 2023 | finance.yahoo.com

Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023

September 15, 2023 | msn.com

NICE recommends Idorsia’s chronic insomnia treatment for UK patients

September 6, 2023 | uk.finance.yahoo.com

Idorsia reacquires the world-wide rights to aprocitentan

August 31, 2023 | finance.yahoo.com

Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager

August 25, 2023 | finance.yahoo.com

Idorsia Ltd (IDIA.SW)

See More Headlines

Receive IDRSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:IDRSF
CUSIP: N/A
CIK: N/A
Web: www.idorsia.com
Phone: (158) 844-0000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Jean-Paul Clozel M.D. (Age 69)
CEO & Executive Director
Comp: $1.52M
Mr. André C. Muller (Age 61)
Executive VP & CFO
Dr. Martine Clozel (Age 69)
Executive VP & Chief Scientific Officer
Mr. Andrew C. Weiss (Age 56)
Senior VP and Head of Investor Relations & Corporate Communications
Mr. Julien Gander L.L.M. (Age 45)
Senior VP, Group General Counsel & Company Secretary
Mr. Alexander Khatuntsev (Age 46)
Senior VP & Head of Global Human Resources
Dr. Guy Braunstein M.D. (Age 68)
Executive VP & Chief Medical Officer
Mr. Olivier Lambert (Age 58)
Senior VP & Head of Technical Operations
Mr. Markus A. Riederer (Age 62)
Senior VP & Head of Drug Discovery Biology
Mr. Christoph Boss (Age 56)
Senior VP & Head of Drug Discovery Chemistry

Key Competitors

View All Competitors

IDRSF Stock Analysis - Frequently Asked Questions

Should I buy or sell Idorsia stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 4 sell ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong sell" IDRSF shares.
View IDRSF analyst ratings or view top-rated stocks.
How have IDRSF shares performed in 2024?: Idorsia's stock was trading at $2.45 at the beginning of 2024. Since then, IDRSF shares have decreased by 17.1% and is now trading at $2.03.
View the best growth stocks for 2024 here.
Are investors shorting Idorsia?: Idorsia saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 8,420,100 shares, a decline of 7.6% from the March 15th total of 9,112,700 shares. Based on an average trading volume of 6,500 shares, the short-interest ratio is presently 1,295.4 days.
View Idorsia's Short Interest.
How do I buy shares of Idorsia?: Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IDRSF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial